Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Recruiting

Phase 2

FDG-PET/CTTesting the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Sponsor:

ECOG-ACRIN Cancer Research Group

Code:

NCT05710328

Conditions

Anatomic Stage II Breast Cancer AJCC v8

Anatomic Stage III Breast Cancer AJCC v8

HER2-Positive Breast Carcinoma

Invasive Breast Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Chemotherapy

Computed Tomography

Fludeoxyglucose F-18

Positron Emission Tomography

Surgical Procedure

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-25. This information was provided to ClinicalTrials.gov by ECOG-ACRIN Cancer Research Group on 2025-01-29.